Phase 1 · NCT05757531
A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants
Disposition of [14C]-LY3437943 Following Subcutaneous Administration in Healthy Male Participants
What this means
The registry describes the study design and status. This label does not mean results have been reported.
Figure / record sourceLast verified 23 Oct 2026
Registry record
Trial details
- Trial
- A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants
- ClinicalTrials.gov ID
- NCT05757531
- Indication
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 7
- Status
- Completed
- Interventions
- Drug: [¹⁴C]-LY3437943
- Comparator
- Not reported
- Eligible ages
- 18 Years – 55 Years
- Locations
- 1 site · United States
- Study start
- 17 Mar 2023
- Primary completion
- 23 Jun 2023
- Study completion
- 23 Jun 2023
Verification
- Last verified
- 23 Oct 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 5 Jul 2023
Endpoints
Primary
Urinary Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered; Fecal Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Secondary
PK: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC (0-∞)) of Total Radioactivity and [¹⁴C]-LY3437943; PK: Maximum Concentration (Cmax) of Total Radioactivity and [¹⁴C]-LY3437943; Total Radioactivity Recovered in Urine, Feces, and Expired Air (if applicable); Total Number of Metabolites of LY3437943